Barry D. Bertolet, M.D., FACC
Principal Investigator
SPIRIT III
A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with De Novo Native Coronary Artery Lesions
Summary: This study is being conducted to determine the safety and efficacy of the XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) for the treatment of subjects with a maximum of two de novo native coronary artery lesions.